ISA Pharmaceuticals and Cancer Focus Fund United Kingdom United States of America Netherlands

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma

View original content:https://www.prnewswire.co.uk/news-releases/isa-pharmaceuticals-and-cancer-focus-fund-announce-5-million-investment-to-support-first-in-human-trial-of-isas-novel-immunotherapy-isa103-in-uveal-melanoma-301712579.html